

Axel Heidenreich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3598141/publications.pdf>

Version: 2024-02-01

227
papers

17,596
citations

30070

54
h-index

13771

129
g-index

245
all docs

245
docs citations

245
times ranked

13341
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. <i>European Urology Oncology</i> , 2022, 5, 285-295.	5.4	4
2	Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours. <i>British Journal of Cancer</i> , 2022, 126, 937-947.	6.4	8
3	Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210868.	3.2	4
4	COVID-19 Infection Induce miR-371a-3p Upregulation Resulting in Influence on Male Fertility. <i>Biomedicines</i> , 2022, 10, 858.	3.2	5
5	Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 187-198.	3.9	7
6	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 825-832.	0.8	2
7	Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery. <i>European Urology Open Science</i> , 2022, 40, 117-124.	0.4	1
8	The Current Status of Kidney Cancer Urine Markers – A systematic review. <i>Kidney Cancer</i> , 2022, , 1-6.	0.4	0
9	Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study. <i>World Journal of Urology</i> , 2021, 39, 2515-2523.	2.2	9
10	Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. <i>European Urology Oncology</i> , 2021, 4, 802-810.	5.4	22
11	Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. <i>European Urology Oncology</i> , 2021, 4, 121-123.	5.4	5
12	Editorial: Novel surgical techniques in urology. <i>Current Opinion in Urology</i> , 2021, 31, 1.	1.8	0
13	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). <i>World Journal of Urology</i> , 2021, 39, 3407-3414.	2.2	4
14	Salvage radical prostatectomy after local radiotherapy in prostate cancer. <i>Current Opinion in Urology</i> , 2021, 31, 194-198.	1.8	5
15	Targeted Therapy in Patients with Metastatic Male Germ Cell Tumors. <i>Urologia Internationalis</i> , 2021, 105, 1-4.	1.3	4
16	The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2021, 31, 178-187.	1.8	11
17	Salvage management of patients with relapsing testicular germ cell tumors. <i>Current Opinion in Urology</i> , 2021, 31, 206-213.	1.8	3
18	The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens. <i>Translational Andrology and Urology</i> , 2021, 10, 1647-1655.	1.4	12

#	ARTICLE	IF	CITATIONS
19	Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune-oncology) Tj ETQq1 1 0.784314 rgBT /Ove Journal of Clinical Oncology, 2021, 39, TPS5100-TPS5100.	1.6	8
20	Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer. European Urology, 2021, 79, 605-606.	1.9	5
21	Editorial: Salvage therapy in uro-oncology. Current Opinion in Urology, 2021, 31, 177.	1.8	0
22	The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. Prostate, 2021, 81, 765-771.	2.3	4
23	Safety and mid-term surgical results of anterior urethroplasty with the tissue-engineered oral mucosa graft MukoCell [®] : A single-center experience. International Journal of Urology, 2021, 28, 936-942.	1.0	4
24	Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. Part 1. Current Opinion in Urology, 2021, 31, 297-303.	1.8	8
25	Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2. Current Opinion in Urology, 2021, 31, 304-314.	1.8	11
26	Non-invasive urine markers for the differentiation between RCCs and oncocytoma. Journal of Clinical Laboratory Analysis, 2021, 35, e23762.	2.1	6
27	Personalized Follow-up in Clinical Stage I Testicular Germ Cell Tumors: The Future is Beginning. European Urology Oncology, 2021, 4, 492-493.	5.4	1
28	Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review. Translational Andrology and Urology, 2021, 10, 3167-3175.	1.4	9
29	Intermediate-risk Prostate Cancer – A Sheep in Wolf’s Clothing?. European Urology Oncology, 2021, . .	5.4	0
30	Management of Late Relapses in Metastatic Testicular Germ Cell Tumors: Still a Challenge. European Urology Open Science, 2021, 30, 11-12.	0.4	0
31	Manual kidney stone size measurements in computed tomography are most accurate using multiplanar image reformatations and bone window settings. Scientific Reports, 2021, 11, 16437.	3.3	9
32	Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection – A 13-year follow-up analysis of a phase III trial cohort. European Journal of Cancer, 2021, 155, 64-72.	2.8	10
33	Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 838.e7-838.e13.	1.6	3
34	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clinical Cancer Research, 2021, 27, 6677-6686.	7.0	12
35	Lymph Node Assessment in Prostate Cancer. Clinical Nuclear Medicine, 2021, 46, 303-309.	1.3	8
36	Predictors for Outcome and Complications Related to Urinary Diversion. Anticancer Research, 2021, 41, 5585-5591.	1.1	1

#	ARTICLE	IF	CITATIONS
37	Retroperitoneale Lymphadenektomie. , 2021, , 461-466.		0
38	Contemporary options and future perspectives: three examples highlighting the challenges in testicular cancer imaging. World Journal of Urology, 2021, , 1.	2.2	7
39	Primary Retroperitoneal Lymph Node Dissection or Chemotherapy in Nonseminomas with Low-Volume Metastatic Disease: Experience Matters. European Urology Oncology, 2020, 3, 207-208.	5.4	0
40	Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. BJU International, 2020, 125, 82-88.	2.5	20
41	Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. American Journal of Pathology, 2020, 190, 323-332.	3.8	20
42	Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease. Current Opinion in Urology, 2020, 30, 90-97.	1.8	15
43	Dose independent characterization of renal stones by means of dual energy computed tomography and machine learning: an ex-vivo study. European Radiology, 2020, 30, 1397-1404.	4.5	26
44	Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. Journal of Clinical Oncology, 2020, 38, 1322-1331.	1.6	23
45	Size and volume of kidney stones in computed tomography: Influence of acquisition techniques and image reconstruction parameters. European Journal of Radiology, 2020, 132, 109267.	2.6	15
46	A risk calculator predicting recurrence in lymph node metastatic penile cancer. BJU International, 2020, 126, 577-585.	2.5	12
47	Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane Library, 2020, 2020, CD013020.	2.8	22
48	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration. Journal of Clinical Oncology, 2020, 38, 3763-3772.	1.6	448
49	Human chorionic gonadotropin- α -positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). European Journal of Cancer, 2020, 132, 127-135.	2.8	8
50	Novel therapies for advanced urologic cancers. Current Opinion in Urology, 2020, 30, 594-601.	1.8	2
51	⁶⁸ Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer. BJU International, 2020, 126, 679-683.	2.5	18
52	Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma. BJU International, 2020, 125, 867-875.	2.5	15
53	Testis-preserving strategies in testicular germ cell tumors and germ cell neoplasia in situ. Translational Andrology and Urology, 2020, 9, S24-S30.	1.4	11
54	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. European Urology, 2020, 78, 661-669.	1.9	74

#	ARTICLE	IF	CITATIONS
55	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , 2020, 78, 779-782.	1.9	16
56	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	1.9	278
57	Pelvic exenteration surgery in patients with locally advanced castration-sensitive and castration-resistant, symptomatic prostate cancer. <i>BJU International</i> , 2020, 126, 342-349.	2.5	8
58	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of ⁶⁸ Ga-PSMA and ¹¹ C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of Urology</i> , 2020, 204, 296-302.	0.4	32
59	Validation and implementation of a mobile app decision support system for quality assurance of tumor boards: Analyzing the concordance rates for testis cancer at a multidisciplinary tumor board of a tertiary referral center.. <i>Journal of Clinical Oncology</i> , 2020, 38, 399-399.	1.6	0
60	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 302-302.	0.4	0
61	A rare case of tined lead migration of InterStim device into the rectum with subsequent novel combined surgical-endoscopic removal technique. <i>Turkish Journal of Urology</i> , 2020, 46, 492-495.	1.3	1
62	Mxi-2 Dependent Regulation of p53 in Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 5539-5544.	1.1	3
63	A rare case of tined lead migration of InterStim device into the rectum with subsequent novel combined surgical-endoscopic removal technique. <i>Turkish Journal of Urology</i> , 2020, 46, 492-495.	1.3	2
64	Managing Nonmetastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 285-293.	1.9	125
65	<scp>PSA</scp> persistence after radical prostatectomy needs more than standard therapeutic options to improve outcomes. <i>BJU International</i> , 2019, 124, 716-718.	2.5	0
66	European Association of Urology Guidelines on Testis Cancer: Important Take Home Messages. <i>European Urology Focus</i> , 2019, 5, 742-744.	3.1	20
67	External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 809.e9-809.e18.	1.6	12
68	Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. <i>BMC Cancer</i> , 2019, 19, 12.	2.6	36
69	Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 348-355.e5.	1.9	27
70	Efficacy of the Oestrogen Antagonist Tamoxifen on Sperm Parameters in Patients with Idiopathic Oligoathenoteratozoospermia. <i>Urologia Internationalis</i> , 2019, 103, 108-115.	1.3	2
71	Multidisciplinary Team Meetings for Prostate Cancer Treatment: We Can Do Much Better in Daily Life. <i>Oncology Research and Treatment</i> , 2019, 42, 363-365.	1.2	8
72	Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 531.e7-531.e15.	1.6	27

#	ARTICLE	IF	CITATIONS
73	Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1412-1423.	1.6	246
74	Management of residual masses in testicular germ cell tumors. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 291-300.	2.4	7
75	Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review. <i>European Urology</i> , 2019, 75, 464-476.	1.9	65
76	Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 107, 186-195.	2.8	11
77	Predictors of thrombosis in testicular cancer during platinum-based chemotherapy. <i>World Journal of Urology</i> , 2019, 37, 1907-1916.	2.2	22
78	Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. <i>European Urology</i> , 2019, 75, 604-611.	1.9	197
79	Management of Metastatic Castration- Na^{Ave} Prostate Cancer. , 2019, , 1-12.		0
80	Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Tumors of the Testis. , 2019, , 1-15.		0
81	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. <i>European Urology</i> , 2019, 75, 176-183.	1.9	101
82	Websites on Bladder Cancer: an Appropriate Source of Patient Information?. <i>Journal of Cancer Education</i> , 2019, 34, 381-387.	1.3	13
83	Maligne Hodentumoren: Therapie des Primärtumors. <i>Springer Reference Medizin</i> , 2019, , 1-9.	0.0	0
84	Management of Residual Tumor in Testicular Cancer. , 2019, , 701-705.		0
85	Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Tumors of the Testis. , 2019, , 707-721.		0
86	Refraktäre Hodentumore und Rezidive: Therapie. <i>Springer Reference Medizin</i> , 2019, , 1-8.	0.0	0
87	Management of Metastatic Castration- Na^{Ave} Prostate Cancer. , 2019, , 277-288.		0
88	Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries. <i>World Journal of Urology</i> , 2018, 36, 913-920.	2.2	11
89	Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW – Hormonal therapy, Active Surveillance, Radiation,) Tj ETQq1 1.0.7843 14 rgBT /Ov	1.0	14
90	Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer – a phase III study (PRINCE). <i>BJU International</i> , 2018, 122, 774-782.	2.5	10

#	ARTICLE	IF	CITATIONS
91	Even "low-dose" cabazitaxel requires careful and meticulous patient selection. <i>BJU International</i> , 2018, 121, 163-164.	2.5	1
92	Non-"risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary. <i>European Urology</i> , 2018, 73, 899-907.	1.9	51
93	Current approaches to incorporation of radium-223 in clinical practice. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 37-47.	3.9	55
94	Anterior Urethroplasty Using a New Tissue Engineered Oral Mucosa Graft: Surgical Techniques and Outcomes. <i>Journal of Urology</i> , 2018, 200, 448-456.	0.4	47
95	Low-Dose Characterization of Kidney Stones Using Spectral Detector Computed Tomography. <i>Investigative Radiology</i> , 2018, 53, 457-462.	6.2	31
96	Testis Sparing Surgery for Benign Testicular Masses: Diagnostics and Therapeutic Approaches. <i>Journal of Urology</i> , 2018, 200, 353-360.	0.4	43
97	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	1.9	488
98	Non-"Guideline-concordant Treatment of Testicular Cancer Is Associated With Reduced Relapse-free Survival. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e243-e250.	1.9	16
99	Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. <i>Journal of Urology</i> , 2018, 199, 147-154.	0.4	33
100	Testicular Cancer on the Web"an Appropriate Source of Patient Information in Concordance with the European Association of Urology Guidelines?. <i>Journal of Cancer Education</i> , 2018, 33, 1314-1322.	1.3	9
101	Diagnosis and management of the growing teratoma syndrome: A single-center experience and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 529.e23-529.e30.	1.6	13
102	Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer. <i>Oncology Research and Treatment</i> , 2018, 41, 370-378.	1.2	17
103	Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. <i>European Urology</i> , 2018, 74, 525-526.	1.9	2
104	Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. <i>European Urology Oncology</i> , 2018, 1, 46-53.	5.4	53
105	Interdisciplinary Management of Testicular Germ Cell Tumors - More Needed than Ever!. <i>Oncology Research and Treatment</i> , 2018, 41, 354-355.	1.2	2
106	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 548-555.e3.	1.9	37
107	Results of Use of Tissue-Engineered Autologous Oral Mucosa Graft for Urethral Reconstruction: A Multicenter, Prospective, Observational Trial. <i>EBioMedicine</i> , 2017, 23, 185-192.	6.1	58
108	Predictive Factors for Developing Venous Thrombosis during Cisplatin-Based Chemotherapy in Testicular Cancer. <i>Urologia Internationalis</i> , 2017, 99, 104-109.	1.3	21

#	ARTICLE	IF	CITATIONS
109	Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen. <i>Radiology</i> , 2017, 285, 493-505.	7.3	197
110	Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. <i>European Urology</i> , 2017, 71, 534-542.	1.9	28
111	Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2291.	4.1	40
112	Online Discussion on #KidneyStones: A Longitudinal Assessment of Activity, Users and Content. <i>PLoS ONE</i> , 2016, 11, e0160863.	2.5	20
113	Role of salvage lymph node dissection in prostate cancer. <i>Current Opinion in Urology</i> , 2016, 26, 581-589.	1.8	28
114	Metastatic surgery in testis cancer. <i>Current Opinion in Urology</i> , 2016, 26, 590-595.	1.8	5
115	Palliative Radical (Cysto-)prostatectomy for Locally Advanced, Symptomatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 478-479.	3.1	9
116	Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. <i>Lancet Oncology</i> , The, 2016, 17, 1306-1316.	10.7	259
117	Surgical resection of metastases in patients with urogenital malignancies. <i>Current Opinion in Urology</i> , 2016, 26, 564-565.	1.8	0
118	Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome. <i>World Journal of Urology</i> , 2016, 34, 1061-1066.	2.2	12
119	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 153-163.	10.7	210
120	Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with ⁶⁸ Ga-PSMA-HBED-CC than with ¹⁸ F-Fluoroethylcholine PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1410-1417.	6.4	125
121	Extent of disease in recurrent prostate cancer determined by [⁶⁸ Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 397-403.	6.4	162
122	Analysis of drug-related problems in three departments of a German University hospital. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 119-126.	2.1	47
123	Therapie des metastasierten Hodentumors. , 2016, , 1755-1763.		0
124	Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS. <i>BioMed Research International</i> , 2015, 2015, 1-23.	1.9	44
125	The Role of Palliative Surgery in Castration-Resistant Prostate Cancer. <i>Oncology Research and Treatment</i> , 2015, 38, 670-677.	1.2	20
126	Cytoreductive Radical Prostatectomy in Patients with Prostate Cancer and Low Volume Skeletal Metastases: Results of a Feasibility and Case-Control Study. <i>Journal of Urology</i> , 2015, 193, 832-838.	0.4	225

#	ARTICLE	IF	CITATIONS
127	Risk and timing of biochemical recurrence in pT3aNO/Nx prostate cancer with positive surgical margin â€œ A multicenter study. Radiotherapy and Oncology, 2015, 116, 119-124.	0.6	16
128	Cholineâ€œpositron emission tomography/<scp>CT</scp> in patients with relapsing prostate cancer: to be performed with therapeutic consequences only. BJU International, 2015, 115, 849-850.	2.5	3
129	cfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer. Journal of Urology, 2015, 194, 966-971.	0.4	39
130	Sequencing AR-targeted agents might be ineffective in mCRPC. Nature Reviews Urology, 2015, 12, 246-247.	3.8	1
131	Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients.. Journal of Clinical Oncology, 2015, 33, 5034-5034.	1.6	12
132	Postchemotherapy Retroperitoneal Lymph Node Dissection. , 2015, , 91-98.		0
133	Extended pelvic lymphadenectomy in prostate cancer: Practice makes perfect. Canadian Urological Association Journal, 2015, 9, 232.	0.6	2
134	TERRAIN.. Journal of Clinical Oncology, 2015, 33, 5049-5049.	1.6	0
135	Prospective clinical phase-II trial on docetaxel and estramustine with or without epoetin-Î± in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, e16064-e16064.	1.6	1
136	Treatment sequencing for CRPCâ€œwhat do we know?. Nature Reviews Urology, 2014, 11, 189-190.	3.8	9
137	Pelvic Lymphadenectomy in Clinically Localised Prostate Cancer: Counting Lymph Nodes or Dissecting Primary Landing Zones of the Prostate?. European Urology, 2014, 66, 447-449.	1.9	2
138	Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme. European Journal of Cancer, 2014, 50, 1090-1099.	2.8	88
139	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. European Urology, 2014, 65, 467-479.	1.9	1,304
140	EAU Guidelines on Prostate Cancer. Part I: Screening, Diagnosis, and Local Treatment with Curative Intentâ€œUpdate 2013. European Urology, 2014, 65, 124-137.	1.9	1,613
141	Editorial Comment. Urology, 2014, 84, 168.	1.0	0
142	Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncology, The, 2014, 15, e404-e414.	10.7	196
143	A Multicenter Phase 1 Study of EMD 525797 (DI17E6), a Novel Humanized Monoclonal Antibody Targeting Î±v Integrins, in Progressive Castration-resistant Prostate Cancer with Bone Metastases After Chemotherapy. European Urology, 2014, 65, 897-904.	1.9	40
144	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. European Journal of Cancer, 2014, 50, 1617-1627.	2.8	133

#	ARTICLE	IF	CITATIONS
145	Radical retropubic and perineal prostatectomy for clinically localised prostate cancer in renal transplant recipients. Arab Journal of Urology Arab Association of Urology, 2014, 12, 142-148.	1.5	18
146	German second-opinion network for testicular cancer: Sealing the leaky pipe between evidence and clinical practice. Oncology Reports, 2014, 31, 2477-2481.	2.6	28
147	Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group.. Journal of Clinical Oncology, 2014, 32, 109-109.	1.6	0
148	Surgical management of testicular cancer patients with complex postchemotherapy residual masses: Aachen University experience.. Journal of Clinical Oncology, 2014, 32, 387-387.	1.6	0
149	Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).. Journal of Clinical Oncology, 2014, 32, 242-242.	1.6	1
150	Complications during cisplatin-based primary chemotherapy in patients with testicular cancer: Is there a need for thromboembolic prophylaxis?. Journal of Clinical Oncology, 2014, 32, 371-371.	1.6	0
151	Cytoreductive radical prostatectomy (CRP) in patients with prostate cancer (PCA) and low-volume osseous metastases.. Journal of Clinical Oncology, 2014, 32, 272-272.	1.6	0
152	Early Detection of Prostate Cancer: European Association of Urology Recommendation. European Urology, 2013, 64, 347-354.	1.9	133
153	Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme. European Urology, 2013, 63, 977-982.	1.9	70
154	Editorial Comment. Urology, 2013, 82, 1360-1361.	1.0	0
155	Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC).. Journal of Clinical Oncology, 2013, 31, 5001-5001.	1.6	13
156	Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. Journal of Clinical Oncology, 2013, 31, 5055-5055.	1.6	1
157	Randomized, double-blind, placebo-controlled proof of concept study of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who experience response or stabilization during first-line docetaxel chemotherapy.. Journal of Clinical Oncology, 2013, 31, TPS5098-TPS5098.	1.6	1
158	Therapies Used in Prostate Cancer Patients by European Urologists: Data on Indication with a Focus on Expectations, Perceived Barriers and Guideline Compliance Related to the Use of Bisphosphonates. Urologia Internationalis, 2012, 89, 30-38.	1.3	10
159	Contemporary Management of Postchemotherapy Testis Cancer. European Urology, 2012, 62, 867-876.	1.9	96
160	Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice. Therapeutic Advances in Urology, 2012, 4, 187-205.	2.0	50
161	Organâ€preserving surgery for testicular tumours. BJU International, 2012, 109, 474-490.	2.5	29
162	Residual Tumor Size and IGCCCG Risk Classification Predict Additional Vascular Procedures in Patients with Germ Cell Tumors and Residual Tumor Resection: A Multicenter Analysis of the German Testicular Cancer Study Group. European Urology, 2012, 61, 403-409.	1.9	82

#	ARTICLE	IF	CITATIONS
163	High-Risk Prostate Cancer: From Definition to Contemporary Management. <i>European Urology</i> , 2012, 61, 1096-1106.	1.9	119
164	Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 243-243.	1.6	4
165	Surgical Resection of Urological Tumor Metastases Following Medical Treatment. <i>Deutsches Arzteblatt International</i> , 2012, 109, 631-7.	0.9	19
166	A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results. <i>Journal of Clinical Oncology</i> , 2012, 30, e15112-e15112.	1.6	0
167	Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy. <i>Archivos Espanoles De Urologia</i> , 2012, 65, 215-26.	0.2	4
168	Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. <i>Acta Oncologica</i> , 2011, 50, 127-133.	1.8	7
169	Interpreting the Clinical Significance of Quality of Life Score Changes after Radiotherapy for Localized Prostate Cancer. <i>Current Urology</i> , 2011, 5, 137-144.	0.6	13
170	Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy. <i>BJU International</i> , 2011, 107, 220-225.	2.5	39
171	The Role of Choline Positron Emission Tomography/Computed Tomography in the Management of Patients with Prostate-Specific Antigen Progression After Radical Treatment of Prostate Cancer. <i>European Urology</i> , 2011, 59, 51-60.	1.9	177
172	EAU Guidelines on Prostate Cancer. Part I: Screening, Diagnosis, and Treatment of Clinically Localised Disease. <i>European Urology</i> , 2011, 59, 61-71.	1.9	1,299
173	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2011, 59, 572-583.	1.9	459
174	Prognostic Parameters, Complications, and Oncologic and Functional Outcome of Salvage Radical Prostatectomy for Locally Recurrent Prostate Cancer after 21st-Century Radiotherapy. <i>European Urology</i> , 2010, 57, 437-445.	1.9	153
175	Burden or Relief: Do Second-Opinion Centers Influence the Quality of Care Delivered to Patients with Testicular Germ Cell Cancer?. <i>European Urology</i> , 2010, 57, 867-872.	1.9	28
176	Organ-Sparing Surgery for Adult Testicular Tumours: A Systematic Review of the Literature. <i>European Urology</i> , 2010, 57, 780-790.	1.9	173
177	Imaging Studies in Metastatic Urogenital Cancer Patients Undergoing Systemic Therapy: Recommendations of a Multidisciplinary Consensus Meeting of the Association of Urological Oncology of the German Cancer Society. <i>Urologia Internationalis</i> , 2010, 85, 1-10.	1.3	45
178	Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2010, 96, 25-29.	0.6	41
179	Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Testicular Cancer: Radical or Modified Template Resection. <i>European Urology</i> , 2009, 55, 217-226.	1.9	179
180	Pelvic Lymph Node Dissection in Prostate Cancer. <i>European Urology</i> , 2009, 55, 1251-1265.	1.9	431

#	ARTICLE	IF	CITATIONS
181	Contralateral testicular biopsy in testis cancer: current concepts and controversies. <i>BJU International</i> , 2009, 104, 1346-1350.	2.5	43
182	Improving Flexibility and Quality of Life for Your Patients: A Must?. <i>European Urology Supplements</i> , 2009, 8, 857-862.	0.1	3
183	Maligne Hodentumoren. , 2009, , 637-738.		0
184	Optimizing treatment for men with advanced prostate cancer: Expert recommendations and the multidisciplinary approach. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, S9-S22.	4.4	28
185	EAU Guidelines on Prostate Cancer. <i>European Urology</i> , 2008, 53, 68-80.	1.9	1,373
186	Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Tumours of the Testis. <i>European Urology</i> , 2008, 53, 260-274.	1.9	79
187	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. <i>European Urology</i> , 2008, 53, 478-496.	1.9	488
188	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. <i>European Urology</i> , 2008, 53, 497-513.	1.9	243
189	Reply to Magdi Kirolosâ€™ Letter to the Editor re: Axel Heidenreich, Gunnar Aus, Michel Bolla et al. <i>EAU Guidelines on Prostate Cancer. Eur Urol</i> 2008;53:68â€“80. <i>European Urology</i> , 2008, 54, 695-697.	1.9	1
190	Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 2966-2972.	1.6	305
191	Anatomical Extent of Pelvic Lymphadenectomy in Patients Undergoing Radical Prostatectomy. <i>European Urology</i> , 2007, 52, 29-37.	1.9	277
192	Guidelines and Counselling for Treatment Options in the Management of Prostate Cancer. , 2007, 175, 131-162.		4
193	588: Prediction of Residual Retroperitoneal Mass Histology following Postchemotherapy Retroperitoneal Surgery for Metastatic Nonseminomatous Germ Cell Tumors: Role of MDR-1 and Mismatch Repair Genes. <i>Journal of Urology</i> , 2007, 177, 197-197.	0.4	4
194	1000: Post-Chemotherapy Retroperitoneal Resection of Residual Masses in Germ Cell Cancer with Modified Template Resection. <i>Journal of Urology</i> , 2007, 177, 330-330.	0.4	6
195	Open versus Laparoscopic Radical Cystectomy. <i>European Urology Supplements</i> , 2006, 5, 385-394.	0.1	9
196	Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. <i>Anti-Cancer Drugs</i> , 2006, 17, 993-996.	1.4	36
197	Re: Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy. <i>European Urology</i> , 2006, 50, 386-387.	1.9	2
198	Impact of evidence-based interdisciplinary guidelines on testis cancer management. <i>Cancer</i> , 2006, 106, 313-319.	4.1	18

#	ARTICLE	IF	CITATIONS
199	Repeat Retroperitoneal Lymphadenectomy in Advanced Testicular Cancer. <i>European Urology</i> , 2005, 47, 64-71.	1.9	67
200	Salvage Radical Prostatectomy. <i>European Urology Supplements</i> , 2005, 4, 47-52.	0.1	2
201	Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 991-1005.	2.4	16
202	Ibandronate in metastatic bone pain. <i>Seminars in Oncology</i> , 2004, 31, 67-72.	2.2	21
203	Surgical management of vesicoureteral reflux in pediatric patients. <i>World Journal of Urology</i> , 2004, 22, 96-106.	2.2	90
204	Preoperative imaging in renal cell cancer. <i>World Journal of Urology</i> , 2004, 22, 307-315.	2.2	119
205	Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. <i>Cancer</i> , 2004, 101, 948-956.	4.1	42
206	Prediction of Necrosis After Chemotherapy of Advanced Germ Cell Tumors: Results of a Prospective Multicenter Trial of the German Testicular Cancer Study Group. <i>Journal of Urology</i> , 2004, 171, 1835-1838.	0.4	125
207	Complications of Primary Nerve Sparing Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Experience of the German Testicular Cancer Study Group. <i>Journal of Urology</i> , 2003, 169, 1710-1714.	0.4	217
208	Bisphosphonates in the Management of Metastatic Prostate Cancer. <i>Oncology</i> , 2003, 65, 5-11.	1.9	27
209	Clinical stage I nonseminomatous testicular germ-cell tumors: surgery or watchful waiting, still an issue?. <i>Current Opinion in Urology</i> , 2002, 12, 427-430.	1.8	17
210	Extended Pelvic Lymphadenectomy In Patients Undergoing Radical Prostatectomy: High Incidence Of Lymph Node Metastasis. <i>Journal of Urology</i> , 2002, 167, 1681-1686.	0.4	578
211	Accuracy of Frozen Section Examination of Testicular Tumors of Uncertain Origin. <i>European Urology</i> , 2002, 41, 290-293.	1.9	131
212	Nephron-Sparing Surgery for Renal Angiomyolipoma. <i>European Urology</i> , 2002, 41, 267-273.	1.9	59
213	Modern Approach of Diagnosis and Management of Acute Flank Pain: Review of All Imaging Modalities. <i>European Urology</i> , 2002, 41, 351-362.	1.9	195
214	Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. <i>Journal of Urology</i> , 2002, 167, 1681-6.	0.4	133
215	RE: MICROSURGICAL TESTICULAR DENERVATION OF THE SPERMATIC CORD AS PRIMARY SURGICAL TREATMENT OF CHRONIC ORCHIALGIA. <i>Journal of Urology</i> , 2001, 166, 2322-2323.	0.4	2
216	ORGAN SPARING SURGERY FOR MALIGNANT GERM CELL TUMOR OF THE TESTIS. <i>Journal of Urology</i> , 2001, 166, 2161-2165.	0.4	318

#	ARTICLE	IF	CITATIONS
217	Microscopic and Biochemical Fertility Characteristics of Semen after Shockwave Lithotripsy of Distal Ureteral Calculi. <i>Journal of Endourology</i> , 2001, 15, 781-785.	2.1	16
218	Quality-of-life issues in the treatment of testicular cancer. <i>World Journal of Urology</i> , 1999, 17, 230-238.	2.2	57
219	Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours. <i>Apmis</i> , 1998, 106, 90-100.	2.0	48
220	Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. <i>Cancer</i> , 1998, 83, 1002-1011.	4.1	160
221	Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. <i>Cancer</i> , 1998, 83, 1002-1011.	4.1	2
222	Synchronous Bilateral Testicular Tumour: Nonseminomatous Germ Cell Tumours and Contralateral Benign Tumours. <i>Scandinavian Journal of Urology and Nephrology</i> , 1997, 31, 389-392.	1.4	24
223	Prognostic risk factors in low stage testicular germ cell tumors. , 1997, 79, 1641-1645.		21
224	Testicular Tissue Oxygen Pressure. <i>Journal of Urology</i> , 1996, 155, 1488-1491.	0.4	25
225	Painless ESWL by Cutaneous Application of Vaseline. <i>Scandinavian Journal of Urology and Nephrology</i> , 1995, 29, 155-160.	1.4	7
226	Organ Preserving Surgery in Testicular Epidermoid Cysts. <i>Journal of Urology</i> , 1995, 153, 1147-1150.	0.4	76
227	Risk Factors for Antisperm Antibodies in Infertile Men. <i>American Journal of Reproductive Immunology</i> , 1994, 31, 69-76.	1.2	113